L&T-TECHNOLOGY-SERVICES
1.2.2024 05:45:26 CET | Business Wire | Press release
L&T Technology Services Limited (BSE: 540115, NSE: LTTS), a leading global digital engineering and R&D services company, supports Marelli, a leading mobility technology supplier to the automotive sector in redefining the landscape of automotive infotainment and information cluster design through the introduction of Marelli’s groundbreaking Digital Twin solutions. By harnessing the power of these innovative solutions, Marelli – supported by LTTS – has drastically streamlined automotive software development processes and reduced prototype costs, heralding a new era in the automotive industry for the development of Software Defined Vehicles (SDV).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240130254637/en/
Marelli's Digital Twin with the support of LTTS, offers a virtual replica of the entire car electric-electronic architecture - from information cluster to infotainment. (Graphic: Business Wire)
Built on Amazon Web Services (AWS), with the support of LTTS, Marelli's Digital Twin provides a virtual replica of the entire car electric-electronic architecture - from information clusters to infotainment, and from Zone Control Units to body. Leveraging Digital Cockpit that runs on the latest generation Snapdragon® Cockpit Platform from Qualcomm Technologies, Inc. and LTTS cloud-based virtualization solutions, Marelli's Digital Twin streamlines software development and prototype creation, cutting costs and accelerating timelines. This innovative solution is set to revolutionize the automotive industry, significantly reducing software development time by up to 70% and prototype costs by up to 30%.
The groundbreaking solution was showcased at the Consumer Electronics Show (CES) 2024, held in Las Vegas in January 2024.
“We are excited to join forces with LTTS in our ongoing efforts to enhance our Digital Twin,” expressed Roberto Secchi, Head of Software Platform and DevOps at Marelli’s Electronic Systems division. “Marelli has become a key player in the SDV arena, thanks to our dedicated investments and the exploration of various business prospects, all driven by our unwavering commitment to innovation. Leveraging LTTS’ capabilities will further boost our product portfolio, reinforcing Marelli as the premier technology partner for automotive companies.”
"We are thrilled to embark on a strategic collaboration with Marelli, leveraging the vast capabilities of software defined mobility, Digital Cockpit systems, connected cars to bolster Marelli's vision to revolutionize the future of mobility," said Abhishek Sinha, Chief Operating Officer and Board Member at L&T Technology Services. "This partnership is not only catalyzing unparalleled efficiencies in automotive software development but also spearheading the future of automotive infotainment through our groundbreaking digital twin offerings. Together, we are pioneering a new era of innovation, setting the stage for the next generation of mobility solutions."
Snapdragon is a trademark or registered trademarks of Qualcomm Incorporated.
Snapdragon is a product of Qualcomm Technologies, Inc. and/or its subsidiaries.
About L&T Technology Services Ltd
L&T Technology Services Limited (LTTS) is a listed subsidiary of Larsen & Toubro Limited focused on Engineering and R&D (ER&D) services. We offer consultancy, design, development and testing services across the product and process development life cycle. Our customer base includes 69 Fortune 500 companies and 57 of the world’s top ER&D companies, across industrial products, medical devices, transportation, telecom & hi-tech, and the process industries. Headquartered in India, we have over 23,200 employees spread across 22 global design centers, 28 global sales offices and 105 innovation labs as of December 31, 2023. For more information, please visit https://www.LTTS.com/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130254637/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom